We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

New Fish Oil-Based Medication Targeting High Cholesterol Will Compete With Lovaza

November 8, 2010: 08:50 AM EST

A new, specialized fish oil medication from Ireland’s Amarin Corp. has entered Phase 3 clinical trials and could offer some competition for GlaxSmithKline’s fish oil-based pharmaceutical Lovaza. The products, combined with statin therapy, are designed to treat patients with hypertriglyceridemia, a condition characterized by a dangerously high triglyceride level (over 500 mg/dL). Amarin’s product, AMR101, is a pure ethyl ester of eicosapentaenoic acid (ethyl-EPA), a long chain highly unsaturated omega-3 fatty acid, but contains no DHA. Even without a DHA component, the company’s data from 19,000 patients show that AMR101 coupled with a statin reduces coronary events by an additional 19 percent, compared to statins alone. According to the company, the product provides other health benefits, including regulation of glucose metabolism.

Joanna Cosgrove, "AMR101 Takes on Lovaza", Nutraceutical World, November 08, 2010, © Rodman Publishing
Vitality & Better Living
United Kingdom
Companies, Organizations
Market News
Products & Brands
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.